Idioma:

Intramuscular Imipenem/Cilastatin in Multiple-Dose Treatment Regimens: Review of the Worldwide Clinical Experience

Garau, Javier ; Calandra, Gary B.

Chemotherapy (Basel), 1991, Vol.37 (Suppl 2), p.44-52 [Periódico revisado por pares]

Basel, Switzerland: Karger

Sem texto completo

Citações Citado por

Enviar para

Título:
Intramuscular Imipenem/Cilastatin in Multiple-Dose Treatment Regimens: Review of the Worldwide Clinical Experience
Autor: Garau, Javier ; Calandra, Gary B.
Assuntos: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial Infections - drug therapy ; Biological and medical sciences ; Cilastatin - administration & dosage ; Cilastatin - therapeutic use ; Drug Combinations ; Female ; Humans ; Imipenem - administration & dosage ; Imipenem - therapeutic use ; Imipenem/Cilastatin: Experience with a Long-Acting Intramuscular Formulation ; Injections, Intramuscular ; Male ; Medical sciences ; Middle Aged ; Pelvic Inflammatory Disease - drug therapy ; Pharmacology. Drug treatments ; Respiratory Tract Infections - drug therapy ; Skin Diseases, Infectious - drug therapy ; United States ; Urinary Tract Infections - drug therapy
É parte de: Chemotherapy (Basel), 1991, Vol.37 (Suppl 2), p.44-52
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Multicenter noncomparative trials of intramuscular administration of imipenem/cilastatin for the treatment of a variety of infections requiring multiple-dose therapy are reviewed. Fourteen centers in the United States and 18 centers elsewhere participated in these studies. A total of 686 patients (461 evaluable) were treated worldwide. The severity of the infection was rated as moderate in 58.9%, mild in 37.2% and severe in 0.6%. The most common sites of infection were the skin and soft tissue (36.2%) and intra-abdominal (17.6%). Polymicrobial infections were relatively common (27%). Dosing regimens in evaluable patients were 500 mg every 12 h (45.1%), 750 mg every 12 h (36.2%) and 500 mg every 8 h (18.6%). The overall clinical outcome was favorable (clinical cure or improvement) for 95% or more of the evaluable patients with the various body system infections, except in gynecologic infections where 89% of the evaluable patients had a favorable outcome and for sepsis where the favorable outcome was 76%. Where data were available for analysis (skin and soft tissue infections) there was no difference in favorable clinical outcome among patients with moderate infection treated with 1.0 g/day (95% favorable) compared with 1.5g/day (94% favorable). The overall bacteriologic eradication rate was 91%. Clinical adverse effects were similar in type but less common in frequency than those noted in other studies with the intravenous formulation, with nausea, vomiting and diarrhea being most common; no instances of seizures or confusion were observed. The laboratory adverse effects were similar to those seen in other studies with the intravenous formulation, with increased liver enzyme values the most common. The intramuscular injection was well tolerated in 87% of the patients and moderately well tolerated in 6.6%. The efficacy and low incidence of side effects of the intramuscular formulation of imipenem/cilastatin are significant advantages in the cost-effective treatment of infections.
Editor: Basel, Switzerland: Karger
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 9 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Intramuscular Imipenem/Cilastatin in Multiple-Dose Treatment Regimens: Review of the Worldwide Clinical Experience

Garau, Javier ; Calandra, Gary B.

Basel, Switzerland: Karger

Buscando em bases de dados remotas. Favor aguardar.